Literature DB >> 19802999

The penetration of ceftazidime into extravascular fluid.

D M Ryan1, U Mason, S M Harding.   

Abstract

Ceftazidime achieved high concentrations in extravascular fluid following intravenal or intramuscular administration to healthy male volunteers. Subcutaneous fluid was sampled using the implanted cotton thread technique. The concentration/time curves of ceftazidime in subcutaneous fluid, after a short distributive phase, were similar in profile to concurrent serum concentrations. The degree of penetration as determined by ratio of the area under curve for subcutaneous fluid levels to the area under curve for the serum levels was 54%. There is evidence from experiments in animals that antibiotic concentration/time profiles in the subcutaneous compartment reflect levels found in rapidly equilibriating tissue fluids or well perfused tissues. It is therefore concluded that ceftazidime will achieve therapeutically useful levels in a wide range of tissues and tissue fluids in man in exess of the MIC90 for Pseudomonas aeruginosa, Staphylococcus aureus and members of the Enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 19802999     DOI: 10.1093/jac/8.suppl_b.283

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

Review 1.  The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy.

Authors:  R Wise
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

2.  Pharmacokinetics of ceftazidime in acutely ill hospitalised elderly patients.

Authors:  M Jonsson; M Walder
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

3.  The pharmacokinetics of ceftazidime in lactating and non-lactating cows.

Authors:  R Rule; G H Quiroga; M Rubio; H O Buschiazzo; P M Buschiazzo
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

Review 4.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.